Coya Therapeutics Inc. (COYA), a clinical-stage biotechnology company, which is optimistic about the strategic opportunities that lie ahead, both with existing and new partners, looks forward to delivering shareholder value in 2025.
The company expects to present additional data from its Phase 2 investigator-initiated study of COYA 302, otherwise known as Low Dose Interleukin-2 (LD IL-2), in patients with mild-to-moderate Alzheimer's next quarter (Q1, 2025).
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.